What Is Bronchogen?
Bronchogen is the name used for an experimental four-amino-acid peptide from the Russian short-peptide bioregulator research programme. It is associated with bronchial epithelium, the sheet of cells lining the airways, and has been studied in cell cultures and rat models of lung injury.
Its identity needs care. Several papers describe the sequence as Ala-Glu-Asp-Leu, abbreviated AEDL, while other indexed papers print Ala-Asp-Glu-Leu, or ADEL. Swapping glutamic acid and aspartic acid produces a different sequence. Without a consistent analytical reference, those names should not be treated as automatically interchangeable.
No published trial was identified in which people with asthma, chronic obstructive pulmonary disease or another respiratory condition received Bronchogen. It is not an approved respiratory medicine.
What is Bronchogen made from?
The most frequently stated sequence in later English summaries is:
`Ala-Glu-Asp-Leu (AEDL)`
The four residues are alanine, glutamic acid, aspartic acid and leucine. A tetrapeptide has three peptide bonds joining four amino acids.
However, the title and abstract of a 2011 DNA study call Bronchogen Ala-Asp-Glu-Leu, which would be ADEL. A 2014 bronchial-cell paper also uses ADEL, while a 2012 cell-differentiation paper uses AEDL. This may reflect a reporting or translation error, but the accessible records do not resolve it.
Chemical sequence determines three-dimensional behaviour, enzyme breakdown and target binding. A trustworthy research report should state which molecule was tested and confirm it analytically.
What does “peptide bioregulator” mean here?
The term comes from work associated with Vladimir Khavinson and colleagues, who proposed that very short peptides could influence gene activity in selected tissues. Different sequences were linked with bronchial, pancreatic, vascular and other cell types.
This is a research framework, not a recognised medicine category established by the United States Food and Drug Administration, the United Kingdom Medicines and Healthcare products Regulatory Agency or the European Medicines Agency. Describing a peptide as bronchial or tissue-specific does not prove that it travels selectively to the lungs after entering the body.
What did the bronchial-cell studies find?
One study used cultures of human embryonic bronchial epithelial cells at early and later passages. A passage occurs when cells are transferred into a fresh culture vessel so they can continue growing. Later-passage cells can display features associated with cellular ageing.
The authors reported that Bronchogen influenced expression of CXCL12 and Hoxa3, factors involved in cell signalling and development. They described the response as tissue-specific when comparing bronchial cells with pancreatic cells and prostate fibroblasts exposed to other short peptides.
A later paper measured Ki67, Mcl-1, p53, CD79 and endothelial nitric oxide synthase. These proteins are associated with cell division, survival, stress responses and signalling. The peptide changed measured levels at different passages.
Human origin does not make this a human treatment study. The cells were cultured outside the body, and altered marker expression does not show healthier airways, fewer infections or better lung function.
What did the DNA study show?
Researchers used calorimetry to measure how the peptide affected the temperature at which DNA strands separate. Bronchogen increased the melting temperature of calf-thymus and mouse-liver DNA under the test conditions. The authors interpreted this as stabilisation of DNA structure.
This physical interaction was measured in a test system, not in living human airways. Calf and mouse DNA are not evidence of selective binding to human bronchial genes. A change in DNA melting temperature cannot establish protection against ageing, mutation or lung disease.
The study is also where the sequence is printed as Ala-Asp-Glu-Leu. That unresolved identity issue limits how confidently its result can be combined with papers using Ala-Glu-Asp-Leu.
What did the rat lung study find?
Researchers exposed rats intermittently to nitrogen dioxide for 60 days to produce features resembling chronic obstructive lung damage. Nitrogen dioxide is an irritating gas that injures airway tissue. This model produced inflammatory-cell infiltration, excess mucus-producing goblet cells, replacement of normal airway cells and emphysema-like changes.
The published abstract says one month of Bronchogen treatment reduced several structural abnormalities and helped restore ciliated cells, whose moving surface hairs help clear mucus. These are tissue findings examined under a microscope.
The model cannot reproduce the full human condition called chronic obstructive pulmonary disease, usually shortened to COPD. Human COPD develops over years and involves variable exposure history, infection risk, symptoms and loss of lung function. The abstract does not establish effects on breathing tests or long-term outcomes.
Was inflammation studied separately?
A related rat report examined neutrophils, immune cells that respond rapidly to injury and infection, after nitrogen-dioxide exposure. It described changes in neutrophil activity with peptide treatment.
Immune responses can be protective or damaging depending on timing and cause. Lowering a cell marker in an artificial injury model is not proof that the peptide would safely prevent inflammation in asthma, COPD, pneumonia or another human disease.
How was Bronchogen developed?
| Period | Development |
|---|---|
| 1970s onward | Soviet and Russian researchers developed tissue-derived peptide preparations and later proposed short synthetic sequences |
| 2000s | Bronchogen appeared within the organ-associated short-peptide programme |
| 2011 | A biophysical paper reported DNA thermostability results and printed the sequence as ADEL |
| 2012 to 2014 | Cell studies reported changes in differentiation and protein-expression markers, using both AEDL and ADEL descriptions |
| 2015 | Rat obstructive-lung research reported microscopic changes in damaged airways |
| Current position | Preclinical compound without a published human treatment trial or Western regulatory approval |
No conventional Phase I programme was identified. Phase I normally provides the first structured evidence about human exposure, how a compound moves through the body and its early safety.
How is Bronchogen synthesised and characterised?
A defined tetrapeptide can be made by solid-phase peptide synthesis. Protected amino-acid building blocks are joined in the intended order while the growing chain remains attached to a resin. The finished peptide is released, its protecting groups are removed, and purification separates the main product from incomplete or incorrectly joined sequences.
Sequence confirmation is especially important here because AEDL and ADEL have the same overall amino-acid composition and molecular mass. A simple mass result may therefore fail to tell them apart. Tandem mass spectrometry, amino-acid sequence analysis, comparison with a verified reference and chromatography can help establish which order is present.
Regulated sterile manufacture would also require controls for peptide content, related impurities, counterions, water, particles, bacterial endotoxins, sterility, batch consistency and stability. A label carrying the Bronchogen name does not prove that these standards were met. This is an educational overview, not a manufacturing procedure.
Has Bronchogen been studied in people?
No published human treatment study was identified in the indexed literature reviewed through October 2026. Experiments on cultured human embryonic cells do not establish exposure or benefit in a person.
There is no dependable evidence for effects on cough, sputum, breathlessness, exercise capacity, spirometry, asthma attacks, COPD exacerbations, infection, admission to hospital or survival.
What is known about pharmacokinetics and safety?
No modern human study defines absorption, breakdown, half-life, lung exposure or clearance. Very short peptides may be broken down quickly into amino acids, but the rate and biological consequences need direct measurement.
The published record is too limited to define common or serious adverse effects. Relevant questions include allergic reactions, immune disruption, unintended gene effects and impurities. People with respiratory disease can deteriorate quickly, so using an unproved compound in place of established care could also cause harm through delay.
Is Bronchogen approved?
Bronchogen is not approved by the FDA, MHRA or EMA for COPD, asthma, lung injury or any other condition. Marketing availability, a product name or its history within Russian peptide research does not establish approval.
How strong is the evidence overall?
| Question | Best available evidence | Defensible conclusion |
|---|---|---|
| Does Bronchogen affect bronchial cells? | Cultured human embryonic cells | Selected markers changed |
| Does it interact with DNA? | Calf and mouse DNA test system | A physical effect was reported |
| Does it affect injured lungs? | Nitrogen-dioxide rat model | Microscopic changes were reported |
| Does it improve human respiratory disease? | No treatment trial identified | Unknown |
| Is its precise sequence consistently reported? | Conflicting primary-paper notation | No |
| Is it safe or approved? | No adequate human safety data or approval | No established safety; not approved |
Frequently asked questions
What is Bronchogen?
It is the name used for an experimental four-amino-acid peptide associated with bronchial-cell research.
What is its amino-acid sequence?
Papers conflict between Ala-Glu-Asp-Leu, or AEDL, and Ala-Asp-Glu-Leu, or ADEL. The discrepancy is unresolved in the accessible record.
Is Bronchogen a natural human peptide?
It is described as a synthetic short peptide, not an established circulating human hormone.
Does Bronchogen treat COPD?
No human clinical trial establishes that it improves COPD symptoms, lung function or flare-ups.
Does it treat asthma?
No dependable human evidence supports treatment of asthma.
Were human cells studied?
Yes, cultured human embryonic bronchial cells were used. That remains laboratory evidence.
What did animal research show?
A rat injury model reported changes in airway structure and inflammation after treatment.
Does Bronchogen repair DNA?
No. A test-tube study measured DNA melting temperature, which does not demonstrate DNA repair in people.
Is Bronchogen known to be safe?
No comprehensive human safety profile exists.
Is Bronchogen approved?
It is not approved by the FDA, MHRA or EMA.
Sources
Research reviewed through October 2026.